Successful Empirical Antifungal Therapy of Intravenous Itraconazole with Pharmacokinetic Evidence in Pediatric Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyery | - |
dc.contributor.author | Shin, Donghoon | - |
dc.contributor.author | Kang, Hyoung Jin | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.contributor.author | Lee, Ji Won | - |
dc.contributor.author | Kim, Sung Jin | - |
dc.contributor.author | Kim, Min Sun | - |
dc.contributor.author | Song, Eun Sun | - |
dc.contributor.author | Jang, Mi Kyoung | - |
dc.contributor.author | Park, June Dong | - |
dc.contributor.author | Jang, In-Jin | - |
dc.contributor.author | Park, Kyung Duk | - |
dc.contributor.author | Shin, Hee Young | - |
dc.contributor.author | Ahn, Hyo Seop | - |
dc.date.accessioned | 2023-03-08T18:50:55Z | - |
dc.date.available | 2023-03-08T18:50:55Z | - |
dc.date.issued | 2015-07 | - |
dc.identifier.issn | 1173-2563 | - |
dc.identifier.issn | 1179-1918 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64529 | - |
dc.description.abstract | Background and Objectives Empirical antifungal therapy prevents invasive fungal infections in patients with cancer. This study assessed the empirical efficacy of intravenous itraconazole in pediatric patients undergoing hematopoietic stem cell transplantation, and investigated the pharmacokinetics and clinical implications. Methods Oral itraconazole syrup was started (2.5 mg/kg twice daily) for prophylaxis, and patients with persistent neutropenic fever for more than 2 days were switched to intravenous itraconazole (5 mg/kg twice daily for 2 days for induction and 5 mg/kg daily for maintenance) as empirical treatment. Empirical antifungal efficacy was assessed retrospectively in 159 transplantations, and a full pharmacokinetic study was prospectively conducted in six of these patients. Successful antifungal efficacy was defined as the fulfillment of all components of a five-part composite end point. Results The overall empirical antifungal success rate fulfilling all criteria was 42.1 %. No death or drug-related serious adverse events occurred during the study. Mean trough plasma concentration of itraconazole after oral prophylaxis and intravenous induction were 577.2 and 1659.7 mu g/L, respectively. Mean area under the concentration-time curve of itraconazole and its metabolite at steady state were 42,837 +/- A 24,746 mu g.h/L and 63,094 +/- A 19,255 mu g.h/L. Conclusions Intravenous itraconazole was effective and safe as an empirical antifungal agent in pediatric patients; this was due to the fast and satisfactory increase in drug concentration by switching from oral to intravenous therapy. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ADIS INT LTD | - |
dc.title | Successful Empirical Antifungal Therapy of Intravenous Itraconazole with Pharmacokinetic Evidence in Pediatric Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s40261-015-0297-3 | - |
dc.identifier.bibliographicCitation | CLINICAL DRUG INVESTIGATION, v.35, no.7, pp 437 - 446 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000357266700004 | - |
dc.identifier.scopusid | 2-s2.0-84961204779 | - |
dc.citation.endPage | 446 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 437 | - |
dc.citation.title | CLINICAL DRUG INVESTIGATION | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 뉴질랜드 | - |
dc.subject.keywordPlus | HYDROXYPROPYL-BETA-CYCLODEXTRIN | - |
dc.subject.keywordPlus | MULTIPLE-DOSE PHARMACOKINETICS | - |
dc.subject.keywordPlus | LIPOSOMAL AMPHOTERICIN-B | - |
dc.subject.keywordPlus | ORAL SOLUTION | - |
dc.subject.keywordPlus | NEUTROPENIC PATIENTS | - |
dc.subject.keywordPlus | POPULATION PHARMACOKINETICS | - |
dc.subject.keywordPlus | FUNGAL-INFECTIONS | - |
dc.subject.keywordPlus | PERSISTENT FEVER | - |
dc.subject.keywordPlus | PROPHYLAXIS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.